Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Oct;37(10):2106–2111. doi: 10.1128/aac.37.10.2106

Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

R D Pryka 1, K A Rodvold 1, W Ting 1, S Levitsky 1, R W Frost 1, J T Lettieri 1
PMCID: PMC192236  PMID: 8257131

Abstract

The pharmacokinetic parameters of intravenous ciprofloxacin were examined in five adult male patients on three separate occasions of open heart surgery: the 24 h before cardiopulmonary bypass (CPB) surgery, (PRE), during surgery (SURG), and 48 to 72 h after surgery (POST). Serial blood (n = 16), urine, and SURG tissue samples were collected after intravenous administration of a single 300-mg dose of ciprofloxacin during each study period. All samples were assayed for ciprofloxacin by a specific high-performance liquid chromatographic method. Serum ciprofloxacin concentrations remained constant or continued to decline during the course of CPB surgery. A significant (P < 0.05) decrease in total body clearance was observed during the SURG and POST phases (298 and 306 ml/min/1.73 m2, respectively) compared with that during the PRE phase (364 ml/min/1.73 m2). Renal clearances and elimination half-lives were similar during all three study phases. A nonsignificant decline occurred in the apparent volume of distribution, from mean values of 2.1 and 2.0 liters/kg during the PRE and POST phases, respectively, to 1.7 liters/kg during the SURG phase. The mediastinal fat tissue ciprofloxacin concentrations ranged from 0.45 to 2.89 micrograms/g. Overall, little significant difference was noted in the disposition of intravenous ciprofloxacin during CPB surgery compared with that before and after surgery.

Full text

PDF
2106

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akl B. F., Richardson G. Serum cefazolin levels during cardiopulmonary bypass. Ann Thorac Surg. 1980 Feb;29(2):109–112. doi: 10.1016/s0003-4975(10)61646-3. [DOI] [PubMed] [Google Scholar]
  2. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  3. Buylaert W. A., Herregods L. L., Mortier E. P., Bogaert M. G. Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1989 Jul;17(1):10–26. doi: 10.2165/00003088-198917010-00002. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Culliford A. T., Cunningham J. N., Jr, Zeff R. H., Isom O. W., Teiko P., Spencer F. C. Sternal and costochondral infections following open-heart surgery. A review of 2,594 cases. J Thorac Cardiovasc Surg. 1976 Nov;72(5):714–726. [PubMed] [Google Scholar]
  6. Drusano G. L. An overview of the pharmacology of intravenously administered ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):339–345. [PubMed] [Google Scholar]
  7. Dudley M. N., Ericson J., Zinner S. H. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother. 1987 Nov;31(11):1782–1786. doi: 10.1128/aac.31.11.1782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fong I. W., Baker C. B., McKee D. C. The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-blind randomized trial. J Thorac Cardiovasc Surg. 1979 Dec;78(6):908–913. [PubMed] [Google Scholar]
  9. Goldmann D. A., Hopkins C. C., Karchmer A. W., Abel R. M., McEnany M. T., Akins C., Buckley M. J., Moellering R. C., Jr Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg. 1977 Mar;73(3):470–479. [PubMed] [Google Scholar]
  10. Holley F. O., Ponganis K. V., Stanski D. R. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet. 1982 May-Jun;7(3):234–251. doi: 10.2165/00003088-198207030-00004. [DOI] [PubMed] [Google Scholar]
  11. Joos B., Ledergerber B., Flepp M., Bettex J. D., Lüthy R., Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985 Mar;27(3):353–356. doi: 10.1128/aac.27.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klamerus K. J., Rodvold K. A., Silverman N. A., Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother. 1988 May;32(5):631–635. doi: 10.1128/aac.32.5.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. LeBel M., Vallée F., Bergeron M. G. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother. 1986 Mar;29(3):501–505. doi: 10.1128/aac.29.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lippert S., Josephsen S. D., Jendresen M., Sørensen T. S., Gutschik E. Elimination of cefuroxime and gentamicin during and after open heart surgery. J Antimicrob Chemother. 1989 Nov;24(5):775–780. doi: 10.1093/jac/24.5.775. [DOI] [PubMed] [Google Scholar]
  16. Mertes P. M., Voiriot P., Dopff C., Scholl H., Clavey M., Villemot J. P., Canton P., Dureux J. B. Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. Antimicrob Agents Chemother. 1990 Mar;34(3):398–401. doi: 10.1128/aac.34.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miller K. W., Chan K. K., McCoy H. G., Fischer R. P., Lindsay W. G., Zaske D. E. Cephalothin kinetics: before, during, and after cardiopulmonary bypass surgery. Clin Pharmacol Ther. 1979 Jul;26(1):54–62. doi: 10.1002/cpt197926154. [DOI] [PubMed] [Google Scholar]
  18. Rooney R., Neligan M. C., Hone R., Murray A. Serum concentrations of cephalosporins and the cell saver in cardiopulmonary bypass surgery. J Antimicrob Chemother. 1988 Aug;22(2):266–268. doi: 10.1093/jac/22.2.266. [DOI] [PubMed] [Google Scholar]
  19. Vance-Bryan K., Guay D. R., Rotschafer J. C. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990 Dec;19(6):434–461. doi: 10.2165/00003088-199019060-00003. [DOI] [PubMed] [Google Scholar]
  20. Williams S. V., Nash D. B., Goldfarb N. Differences in mortality from coronary artery bypass graft surgery at five teaching hospitals. JAMA. 1991 Aug 14;266(6):810–815. [PubMed] [Google Scholar]
  21. Wilson A. P. Antibiotic prophylaxis in cardiac surgery. J Antimicrob Chemother. 1988 May;21(5):522–524. doi: 10.1093/jac/21.5.522. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES